2-ethyl-7-fluoro-5,10-dihydro-benzo[b]thieno[2,3-e][1,4]diazepin-4-one | 61325-39-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: 2-ethyl-7-fluoro-5,10-dihydro-benzo[b]thieno[2,3-e][1,4]diazepin-4-one
• 英文别名: Xsuukhuxkqigrw-uhfffaoysa-；2-ethyl-7-fluoro-5,10-dihydrothieno[3,2-c][1,5]benzodiazepin-4-one
• CAS: 61325-39-1
• 化学式: C₁₃H₁₁FN₂OS
• 分子量: 262.308
• InChiKey: XSUUKHUXKQIGRW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  69.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-ethyl-7-fluoro-5,10-dihydro-benzo[b]thieno[2,3-e][1,4]diazepin-4-one 在 吡啶 、 tetraphosphorus decasulfide 作用下， 反应 1.5h， 以93%的产率得到2-ethyl-7-fluoro-5,10-dihydro-4H-thieno<2,3-b><1,5>benzodiazepine-4-thione
  参考文献：
  名称：

  4-Piperazinyl-10H-thieno [2,3-b] [1,5]苯二氮卓类药物可能是抗精神病药。

  摘要：

  合成了一系列的4-取代的10H-theino [2,3-b] [1,5]苯并二氮杂s。已经评估了这些化合物在大鼠中阻止条件回避反应（CAR）和产生僵直的能力，并已与几种典型的和非典型的抗精神病药进行了比较。在临床上，以不产生僵直症的剂量抑制CAR的化合物被认为引起较少的锥体束外副作用。许多化合物（9、12、17、29和34）显示出强大的抗精神病药活性，但在这两个参数上仍保持了良好的活性分离。已准备了三种与[1,5]系列化合物相似的5-哌嗪基-10H-噻吩并[2,3-b] [1,4]苯并二氮杂derivatives衍生物（46-48）进行比较，发现它们没有活性。

  DOI：

  10.1021/jm00182a013
• 作为产物：
  描述：

  2-(2-amino-4-fluoro-anilino)-5-ethyl-thiophene-3-carboxylic acid ethyl ester 在 dimsylsodium 作用下， 以 二甲基亚砜 为溶剂， 生成 2-ethyl-7-fluoro-5,10-dihydro-benzo[b]thieno[2,3-e][1,4]diazepin-4-one
  参考文献：
  名称：

  Chakrabarti,J.K. et al., Journal of the Chemical Society. Perkin transactions I, 1978, p. 937 - 941

  摘要：

  DOI：

文献信息

• Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders
  申请人：Aicher Daniel Thomas

  公开号：US20050203296A1

  公开（公告）日：2005-09-15

  Described herein are antipyschotic compounds of formula (I) wherein, A is an optionally benzo-fused five or six member aromatic ring having zero to three hetero atoms independently selected from N, O, and S; Alk is (C 1-4 ) alkylene optionally substituted with OH, methoxy, ethoxy, or F; Ar is optionally substituted phenyl, naphthyl, monocyclic heteroaromatic, or bicyclic heteroaromatic; R 1 is hydrogen or (C 1-4 ) alkyl optionally substituted with OH, OR 3 , or OCH 2 CH 2 OH, wherein R 3 is (C 1-2 ) alkyl; R 2 is H, (C 1-6 ) alkyl, halogen, fluorinated (C 1-6 ) alkyl, OR 4 , SR 4 , NO 2 , CN, COR 4 , CONR 5 R 6 , SO 2 NR 5 R 6 , NR 5 R 6 , NR 5 COR 4 , NR 5 SO 2 R 4 , or optionally substituted phenyl, wherein R 4 is hydrogen, (C 1-6 ) alkyl, fluorinated (C 1-6 ) alkyl, benzyl, or optionally substituted phenyl, R 5 and R 6 are independently hydrogen, (C 1-6 ) alkyl, or optionally substituted phenyl; Z is one or two substituents independently selected from hydrogen, halogen, (C 1-6 ) alkyl, fluorinated (C 1-6 ) alkyl, OR 7 , SR 7 , NO 2 , CN, COR 7 , CONR 8 R 9 , SO 2 NR 8 R 9 , NR 8 SO 2 R 7 , NR 8 R 9 , or optionally substituted phenyl, wherein R 7 is hydrogen, (C 1-6 ) alkyl, fluorinated alkyl, benzyl, or optionally substituted phenyl, R 8 and R 9 are independently hydrogen, (C 1-6 ) alkyl, or optionally substituted phenyl; and salts, solvates, and crystal forms thereof. Also described are the use of the compounds of formula (a) as antagonists of the dopamine D 2 receptor and as agents for the treatment of psychosis and bipolar disorders, and pharmaceutical formulations of the compounds of formula (I). Also described are compounds useful as intermediates for the synthesis of the compounds of formula (I).

  本文描述了式（I）的抗精神病化合物，其中A是一个选择性地与N、O和S中的零到三个杂原子独立选定的五元或六元芳香环，可以与苯并联；Alk是（C1-4）的烷基，可以选择性地用OH，甲氧基，乙氧基或F取代；Ar是选择性取代的苯基，萘基，单环杂芳基或双环杂芳基；R1是氢或（C1-4）烷基，可以选择性地用OH，OR3或OCH2CH2OH取代，其中R3是（C1-2）烷基；R2是H，（C1-6）烷基，卤素，氟化的（C1-6）烷基，OR4，SR4，NO2，CN，COR4，CONR5R6，SO2NR5R6，NR5R6，NR5COR4，NR5SO2R4或选择性取代的苯基，其中R4是氢，（C1-6）烷基，氟化的（C1-6）烷基，苄基或选择性取代的苯基，R5和R6独立地是氢，（C1-6）烷基或选择性取代的苯基；Z是一个或两个取代基，独立选择自氢，卤素，（C1-6）烷基，氟化的（C1-6）烷基，OR7，SR7，NO2，CN，COR7，CONR8R9，SO2NR8R9，NR8SO2R7，NR8R9或选择性取代的苯基，其中R7是氢，（C1-6）烷基，氟化的烷基，苄基或选择性取代的苯基，R8和R9独立地是氢，（C1-6）烷基或选择性取代的苯基；以及其盐，溶剂化合物和晶体形式。本文还描述了将式（a）的化合物用作多巴胺D2受体的拮抗剂以及用于治疗精神病和双相障碍的药物，以及式（I）的化合物的制药配方。还描述了用于合成式（I）的化合物的中间体。
• Effects of conformationally restricted 4-piperazinyl-10H-thienobenzodiazepine neuroleptics on central dopaminergic and cholinergic systems
  作者：Jiban K. Chakrabarti、Terrence M. Hotten、Sarah E. Morgan、Ian A. Pullar、David M. Rackham、Francesca C. Risius、Susan Wedley、Michael O. Chaney、Noel D. Jones

  DOI：10.1021/jm00352a007

  日期：1982.10

  The levels of antidopaminergic and anticholinergic activities of neuroleptics, 4-piperazinyl-10H-thienobenzodiazepines, are modulated by imposing steric impedence to the piperazine ring. The optimum situation in favor of the anticholinergic action is reached in compound 5, 2,3-dimethyl-7-fluoro-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine, where a maximum activity (equivalent to hyoscine), as measured by the [3H]QNB receptor binding assay, is obtained. The structure-activity relationships found highlight the importance of certain spatial dispositions of the distal piperazine nitrogen (electron lone pair) with respect to the tricyclic system. The evidence for molecular topography of these compounds is presented from X-ray, NMR, and other physical data. The conformational aspects for correspondence to the relevant receptors are discussed.
• CHAKRABARTI J. K.; HORSMAN L.; HOTTEN T. M.; PULLAR I. A.; TUPPER D. E.; +, J. MED. CHEM., 1980, 23, NO 8, 878-884
  作者：CHAKRABARTI J. K.、 HORSMAN L.、 HOTTEN T. M.、 PULLAR I. A.、 TUPPER D. E.、 +

  DOI：——

  日期：——
• CHAKRABARTI J. K.; HICKS T. A.; HOTTEN T. M.; TUPPER D. E., J. CHEM. SOC. PERKIN TRANS., PART 1, 1978, NO 9, 937-941
  作者：CHAKRABARTI J. K.、 HICKS T. A.、 HOTTEN T. M.、 TUPPER D. E.

  DOI：——

  日期：——
• PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES AND THEIR USE AS DOPAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PSYCHOTIC DISORDERS
  申请人：ELI LILLY AND COMPANY

  公开号：EP1492794B1

  公开（公告）日：2007-12-12

表征谱图